ProfileGDS5678 / 1422686_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 77% 76% 78% 77% 73% 73% 74% 73% 75% 77% 77% 74% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0278176
GSM967853U87-EV human glioblastoma xenograft - Control 25.2512877
GSM967854U87-EV human glioblastoma xenograft - Control 35.1098576
GSM967855U87-EV human glioblastoma xenograft - Control 45.5621678
GSM967856U87-EV human glioblastoma xenograft - Control 55.2834277
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6294473
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6232973
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7947674
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7619973
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9615875
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2499477
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2748277
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8616574
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.931175